Sökning: onr:"swepub:oai:research.chalmers.se:66eb855d-c573-4cfc-bdc2-f3cd9593bf94" > Effect of liragluti...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06989naa a2200661 4500 | |
001 | oai:research.chalmers.se:66eb855d-c573-4cfc-bdc2-f3cd9593bf94 | |
003 | SwePub | |
008 | 190509s2019 | |||||||||||000 ||eng| | |
009 | oai:gup.ub.gu.se/285598 | |
009 | oai:prod.swepub.kib.ki.se:231019730 | |
009 | oai:lup.lub.lu.se:49767fef-6d8f-4e10-b4fe-9437a4bad582 | |
024 | 7 | a https://research.chalmers.se/publication/5158792 URI |
024 | 7 | a https://doi.org/10.1002/osp4.3242 DOI |
024 | 7 | a https://research.chalmers.se/publication/5101502 URI |
024 | 7 | a https://gup.ub.gu.se/publication/2855982 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:2310197302 URI |
024 | 7 | a https://lup.lub.lu.se/record/49767fef-6d8f-4e10-b4fe-9437a4bad5822 URI |
040 | a (SwePub)cthd (SwePub)gud (SwePub)kid (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Ahmadi, Shilan Seyedu University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xseysh |
245 | 1 0 | a Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5) |
264 | c 2019-03-18 | |
264 | 1 | b Wiley,c 2019 |
338 | a electronic2 rdacarrier | |
520 | a Aim Use of the glucagon-like peptide 1 receptor agonist liraglutide has been shown to reduce weight. Different types of anthropometric measurements can be used to measure adiposity. This study evaluated the effect of liraglutide on sagittal abdominal diameter, waist circumference, waist-to-hip ratio and adiponectin levels in people with type 2 diabetes (T2D) treated with multiple daily insulin injections (MDI). Materials and methods In the multicentre, double-blind, placebo-controlled MDI-liraglutide trial, 124 individuals with T2D treated with MDI were randomized to either liraglutide or placebo. Basal values of weight, waist circumference, waist-to-hip ratio, sagittal abdominal diameter and adiponectin were compared with measurements at 12 and 24 weeks after randomization. Results Baseline-adjusted mean weight loss was 3.8 +/- 2.9 kg greater in liraglutide than placebo-treated individuals (p < 0.0001). Waist circumference was reduced by 2.9 +/- 4.3 cm and 0.2 +/- 3.6 cm in the liraglutide and placebo groups, respectively, after 24 weeks (baseline-adjusted mean difference: 2.6 +/- 4.0 cm, p = 0.0005). Corresponding reductions in sagittal abdominal diameter were 1.1 +/- 1.7 cm and 0.0 +/- 1.8 cm (baseline-adjusted mean difference: 1.1 +/- 1.7 cm, p = 0.0008). Hip circumference was reduced in patients randomized to liraglutide (baseline-adjusted mean difference between treatment groups: 2.8 +/- 3.8 cm, p = 0.0001), but there was no significant difference between the groups in either waist-to-hip ratio (baseline-adjusted mean difference: 0.0 +/- 0.04 cm, p = 0.51) or adiponectin levels (baseline-adjusted mean difference: 0.8 +/- 3.3 mg L-1, p = 0.17). Lower HbA1c and mean glucose levels measured by masked continuous glucose monitoring at baseline were associated with greater effects of liraglutide on reductions in waist circumference and sagittal abdominal diameter. Conclusions In patients with T2D, adding liraglutide to MDI may reduce abdominal and hip obesity to a similar extent, suggesting an effect on both visceral and subcutaneous fat. Liraglutide had greater effects on reducing abdominal obesity in patients with less pronounced long-term hyperglycaemia but did not affect adiponectin levels. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a Adiponectin | |
653 | a liraglutide | |
653 | a predictive variable | |
653 | a anthropometric measurements | |
700 | 1 | a Filipsson, Karinu Lund University,Lunds universitet,Diabetes lab,Forskargrupper vid Lunds universitet,Lund University Research Groups4 aut0 (Swepub:lu)med-kfp |
700 | 1 | a Dimenaes, H.u Södra Älvsborgs Sjukhus (SÄS),Södra Älvsborg Hospital (SÄS)4 aut |
700 | 1 | a Isaksson, Sofia Sterneru Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xisaks |
700 | 1 | a Imberg, Henrik,d 1991u Chalmers University of Technology4 aut0 (Swepub:cth)imbergh |
700 | 1 | a Sjoeberg, S.u Karolinska Institutet4 aut |
700 | 1 | a Ahrén, Bou Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Diabetes,Forskargrupper vid Lunds universitet,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)med-bah |
700 | 1 | a Dahlqvist, S.u NU-sjukvården,NU Hospital Group4 aut |
700 | 1 | a Gustafsson, T.u Karolinska universitetssjukhuset,Karolinska University Hospital4 aut |
700 | 1 | a Tuomilehto, J.u National Institute for Health and Welfare,King Abdulaziz University,Donau-Universität Krems,Danube University Krems,Finnish National Institute for Health and Welfare4 aut |
700 | 1 | a Hirsch, I. B.u University of Washington,University of Washington, Seattle4 aut |
700 | 1 | a Lind, Marcus,d 1976u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xostem |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org |
773 | 0 | t Obesity Science and Practiced : Wileyg 5:2, s. 130-140q 5:2<130-140x 2055-2238 |
856 | 4 | u https://research.chalmers.se/publication/515879/file/515879_Fulltext.pdfx primaryx freey FULLTEXT |
856 | 4 | u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/osp4.324 |
856 | 4 | u http://dx.doi.org/10.1002/osp4.324x freey FULLTEXT |
856 | 4 8 | u https://research.chalmers.se/publication/515879 |
856 | 4 8 | u https://doi.org/10.1002/osp4.324 |
856 | 4 8 | u https://research.chalmers.se/publication/510150 |
856 | 4 8 | u https://gup.ub.gu.se/publication/285598 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:231019730 |
856 | 4 8 | u https://lup.lub.lu.se/record/49767fef-6d8f-4e10-b4fe-9437a4bad582 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy